Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Announces Pricing of $9.3 Million Financing
SAN DIEGO , March 28, 2017 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, today announced that it has entered into securities purchase agreements with certain
View HTML
Toggle Summary Biocept Announces Revised Presentation Time at the 27th Annual Oppenheimer Healthcare Conference
Company presentation set for March 22 at 1:00 p.m. ET
View HTML
Toggle Summary Biocept to Present at the 27th Annual Oppenheimer Healthcare Conference
SAN DIEGO , March 15, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that David Moskowitz , Vice President of Strategy
View HTML
Toggle Summary Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Testing for Small Cell Lung Cancer to Patients with Lambert Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals to make Biocept's Target Selector™ test available to LEMS patients in Phase III Firdapse® trial to screen for cancer every six months for up to two years, at no cost to patients
View HTML
Toggle Summary Biocept to Present at the 29th Annual ROTH Conference
SAN DIEGO , March 8, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept Reports Fourth Quarter and Full Year 2016 Financial Results
Revenues increased more than five-fold in 2016 and nearly six-fold in the fourth quarter of 2016Company to host conference call at 4:30 p.m. Eastern time today
View HTML
Toggle Summary Biocept to Release 2016 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 7, 2017
SAN DIEGO , Feb. 21, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it will release financial results for the
View HTML
Toggle Summary Biocept Appoints Michael Terry Senior Vice President Commercial Operations
SAN DIEGO , Feb. 15, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces the appointment of Michael Terry to the newly
View HTML
Toggle Summary Biocept's CEO Issues Letter to Stockholders
Highlights key accomplishments and outlines value drivers for 2017
View HTML
Toggle Summary Biocept to Present at the 19th Annual BIO CEO and Investor Conference
SAN DIEGO , Feb. 6, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the management of cancer patients, announces that President and CEO Michael W. Nall will present a corporate overview at the 19 th
View HTML